{"id":1000284,"date":"2026-09-03T11:55:01","date_gmt":"2026-09-03T15:55:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/"},"modified":"2026-09-03T11:55:01","modified_gmt":"2026-09-03T15:55:01","slug":"citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/","title":{"rendered":"Citius Pharmaceuticals to Participate in September 2026 Investor Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <i>Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference<\/i>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\">CRANFORD, N.J.<\/span>, <span class=\"legendSpanClass\">Sept. 3, 2026<\/span> \/PRNewswire\/ &#8212; Citius Pharmaceuticals, Inc. (&#8220;Citius Pharma&#8221; or the &#8220;Company&#8221;) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City.<\/p>\n<p>During his presentations and investor meetings, Mr. Mazur will provide an overview of the Company&#8217;s business and recent developments, including the ongoing commercialization of LYMPHIR<sup>\u00ae<\/sup>\u00a0(denileukin diftitox-cxdl) by the Company&#8217;s majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), and the continued advancement of the Company&#8217;s late-stage pipeline.<\/p>\n<p>\n        <b>Moody Capital Solutions Conference:<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Conference:<\/b>\u00a0Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference<\/li>\n<li>\n          <b>Dates:<\/b>\u00a0September 9\u201310, 2026<\/li>\n<li>\n          <b>Location: <\/b>The Westin New York Grand Central, New York, NY<\/li>\n<li>\n          <b>Presentation Date &amp; Time:<\/b>\u00a0Wednesday, September 9, 2026, 3:15 pm \u2013 4:00 pm ET<\/li>\n<li>\n          <b>Webcast: <\/b><br \/>\n          <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4766315-1&amp;h=556414341&amp;u=https%3A%2F%2Fevent.summitcast.com%2Fview%2FaUaginU35PTsUt9aSGQScM%2FKeTZ32yPXdmVFkSHVPLdHh&amp;a=webcast%C2%A0link\" target=\"_blank\" rel=\"nofollow\">webcast\u00a0link<\/a>\u00a0<br \/>\u00a0<\/li>\n<\/ul>\n<p>\n        <b>H.C. Wainwright Conference:<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Conference:<\/b>\u00a0H.C. Wainwright 28th Annual Global Investment Conference<\/li>\n<li>\n          <b>Dates:<\/b>\u00a0September 14\u201316, 2026<\/li>\n<li>\n          <b>Location:<\/b>\u00a0Lotte New York Palace Hotel, New York, NY<\/li>\n<li>\n          <b>Presentation Date &amp; Time:<\/b>\u00a0Tuesday, September 15, 2026, 2:00 pm \u2013 2:30 pm ET<\/li>\n<li>\n          <b>Webcast:<\/b>\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4766315-1&amp;h=3382620686&amp;u=https%3A%2F%2Fjourney.ct.events%2Fview%2Fd7df24ed-03d2-4d9e-bb77-8db2a0ec666d&amp;a=webcast+link\" target=\"_blank\" rel=\"nofollow\">webcast link<\/a><\/li>\n<\/ul>\n<p>Please note that the presentation dates and times are subject to change. Participants should refer to the final program agenda for up-to-date information.<\/p>\n<p>Investors interested in scheduling a one-on-one meeting with management should contact their conference representative or the Company&#8217;s investor relations team.<\/p>\n<p>\n        <b>About Citius Pharmaceuticals, Inc.<br \/><\/b>Citius<span> Pharmaceuticals, Inc. (<\/span>Nasdaq<span>: <\/span>CTXR<span>) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. <\/span>Citius Pharma<span> owns approximately 62% of <\/span>Citius<span> Oncology. In December 2025, <\/span>Citius<span> Oncology launched <\/span>LYMPHIR<span>, a targeted <\/span>immunotherapy<span> for the treatment of adults with relapsed or refractory Stage I\u2013III <\/span>CTCL<span> who had had at least one prior systemic therapy. <\/span>Citius Pharma&#8217;s<span> late-stage pipeline also includes <\/span>Mino-Lok<sup>\u00ae<\/sup><span>, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and <\/span><span>CITI<\/span><span>-002 (<\/span>Halo-Lido<span>), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for <\/span>Mino-Lok<span> and a Phase 2b trial for <\/span>Halo-Lido<span> were completed in 2023. <\/span>Mino-Lok<span> met primary and secondary endpoints of its Phase 3 trial. <\/span>Citius Pharma<span> is actively engaged with the FDA to outline next steps for both programs. For more information, please visit <\/span><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4766315-1&amp;h=950334774&amp;u=http%3A%2F%2Fwww.citiuspharma.com%2F&amp;a=www.citiuspharma.com\" target=\"_blank\" rel=\"nofollow\">www.citiuspharma.com<\/a><span>.<\/span><\/p>\n<p>\n        <b>About Citius Oncology, Inc.<br \/><\/b>Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I\u2013III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology&#8217;s competitive positioning. For more information, please visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4766315-1&amp;h=171079801&amp;u=http%3A%2F%2Fwww.citiusonc.com%2F&amp;a=www.citiusonc.com\" target=\"_blank\" rel=\"nofollow\">www.citiusonc.com<\/a>.<\/p>\n<p>\n        <b>Investor Contact:<br \/><\/b>Ilanit Allen<br \/><a href=\"mailto:ir@citiuspharma.com\" target=\"_blank\" rel=\"nofollow\">ir@citiuspharma.com<\/a><br \/>908-967-6677 x113<\/p>\n<p>\n        <b>Media Contact:<br \/><\/b>STiR-communications<br \/>Greg Salsburg<br \/><a href=\"mailto:Greg@STiR-communications.com\" target=\"_blank\" rel=\"nofollow\">Greg@STiR-communications.com<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder6180\">\n<p>\n          <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS967916\/Citius-32.jpg?id=OA2927069\" title=\"Citius Pharmaceuticals, a late-stage biopharmaceutical company\" alt=\"Citius Pharmaceuticals, a late-stage biopharmaceutical company\" \/>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=NE39749&amp;sd=2026-09-03\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences-302868503.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences-302868503.html<\/a><\/p>\n<p>SOURCE Citius Pharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE39749&amp;Transmission_Id=202609030830PR_NEWS_USPR_____NE39749&amp;DateId=20260903\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference CRANFORD, N.J., Sept. 3, 2026 \/PRNewswire\/ &#8212; Citius Pharmaceuticals, Inc. (&#8220;Citius Pharma&#8221; or the &#8220;Company&#8221;) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City. During his presentations and investor meetings, Mr. Mazur will provide an overview of the Company&#8217;s business and recent developments, including the ongoing commercialization of LYMPHIR\u00ae\u00a0(denileukin diftitox-cxdl) by the Company&#8217;s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Citius Pharmaceuticals to Participate in September 2026 Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1000284","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference CRANFORD, N.J., Sept. 3, 2026 \/PRNewswire\/ &#8212; Citius Pharmaceuticals, Inc. (&#8220;Citius Pharma&#8221; or the &#8220;Company&#8221;) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City. During his presentations and investor meetings, Mr. Mazur will provide an overview of the Company&#8217;s business and recent developments, including the ongoing commercialization of LYMPHIR\u00ae\u00a0(denileukin diftitox-cxdl) by the Company&#8217;s &hellip; Continue reading &quot;Citius Pharmaceuticals to Participate in September 2026 Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-03T15:55:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS967916\/Citius-32.jpg?id=OA2927069\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Citius Pharmaceuticals to Participate in September 2026 Investor Conferences\",\"datePublished\":\"2026-09-03T15:55:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\\\/\"},\"wordCount\":556,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS967916\\\/Citius-32.jpg?id=OA2927069\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\\\/\",\"name\":\"Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS967916\\\/Citius-32.jpg?id=OA2927069\",\"datePublished\":\"2026-09-03T15:55:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS967916\\\/Citius-32.jpg?id=OA2927069\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS967916\\\/Citius-32.jpg?id=OA2927069\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Citius Pharmaceuticals to Participate in September 2026 Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - Market Newsdesk","og_description":"PR Newswire Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference CRANFORD, N.J., Sept. 3, 2026 \/PRNewswire\/ &#8212; Citius Pharmaceuticals, Inc. (&#8220;Citius Pharma&#8221; or the &#8220;Company&#8221;) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City. During his presentations and investor meetings, Mr. Mazur will provide an overview of the Company&#8217;s business and recent developments, including the ongoing commercialization of LYMPHIR\u00ae\u00a0(denileukin diftitox-cxdl) by the Company&#8217;s &hellip; Continue reading \"Citius Pharmaceuticals to Participate in September 2026 Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-03T15:55:01+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS967916\/Citius-32.jpg?id=OA2927069","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Citius Pharmaceuticals to Participate in September 2026 Investor Conferences","datePublished":"2026-09-03T15:55:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/"},"wordCount":556,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS967916\/Citius-32.jpg?id=OA2927069","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/","name":"Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS967916\/Citius-32.jpg?id=OA2927069","datePublished":"2026-09-03T15:55:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS967916\/Citius-32.jpg?id=OA2927069","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS967916\/Citius-32.jpg?id=OA2927069"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Citius Pharmaceuticals to Participate in September 2026 Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1000284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1000284"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1000284\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1000284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1000284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1000284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}